Skip to content
  • English
  • Business
  • Entertainment
  • National
  • Lifestyle
  • Education
Daily News India

Daily News India

Just another WordPress site

  • English
  • Business
  • Entertainment
  • National
  • Lifestyle
  • Education
  • Toggle search form
  • A Heartwarming Mother’s Day Celebration at IDT Business
  • Dikazo Triples its Revenue Showcasing an Impressive Growth Business
  • ZEEL’s Mind Wars app reaches 111K downloads on Google Play Store! Business
  • Ahmed Mazon, An unique entrepreneur from the fitness industry Business
  • Malako unveils its exclusive range of soft furnishings for bedrooms and bathrooms Business
  • 7th International Diabetes Summit 2023 inaugurated in Pune Business
  • Taking Off The Prejudices Of Mentalism With The Indias Favorite Mentalist-Narpath Raman Lifestyle
  • Dynamic Cables Successfully Participates in Nepal Electric Power Lights, ELECRAMA and MEE Expo Business

DCGI approves Themis Medicare’s VIRALEX® for Covid-19 treatment

Posted on March 5, 2022 By

Enhances both innate & adaptive immunity and strengthens body’s immune response to viral infections

March 5: In a landmark development for the treatment of COVID-19, Themis Medicare Ltd. (Themis), a Pharmaceutical company headquartered in Mumbai with a legacy of over 50 years of making new treatment options available, announced the approval of its antiviral drug VIRALEX® by the Drug Controller General of India (DCGI). As per the results of a double-blind randomized controlled trials (RCT), the drug helps in early relief of the clinical symptoms in mild tomoderateCOVID-19 patients.

Viralex® has been found to be effective and well tolerated in mild to moderate COVID-19, in two Randomized Controlled Clinical Trials conducted on 499 Indian patients.

In line with the DCGI’s current approach for approval of medicines for the management of the ongoing pandemic, approval for VIRALEX® (Generic name: Inosinepranobex) is based on the results of the robust phase 2 and phase 3RCTs conducted in India, and the well-established safety profile of the drug.

As per the results of the Phase 3 Randomized, Double-blind, Placebo-controlled Trial, 80.17% of patients treated with VIRALEX® showed clinical improvement on day 6, which is significantly higher (p<0.001) from that in the controlled group.

(52.38%) among the mild to moderate non-hospitalized COVID-19 patients. Clinical Cure was also significantly higher in the VIRALEX® group as compared to that in the placebo group on day 6 of treatment. There was early improvement and cure from symptoms in patients who received VIRALEX®. This drug was well tolerated by the patients without any serious side effects. The study was conducted during the Delta wave of the pandemic.

Randomized, Double-Blind, Placebo-controlled, Multicentre Trial is considered as the clinical research methodology of the highest global standard for evaluating drugs against diseases. Themis is one of the few companies to submit data from a higher number of patients from RCTs for approval in management of COVID-19.

After detailed deliberation, the drug regulatory authority granted permission to manufacture and market this new drug for restricted emergency use of the drug as an add on therapy for treatment of mild and moderate COVID-19.

VIRALEX® would be available on the prescription.

Based on the promising study results, the drug appears to offer immense clinical benefit to the patients in the early stages of COVID-19, thus reducing the load on the healthcare system.

VIRALEX® is an immune modulatory agent with broad-spectrum antiviral properties. It enhances both innate & adaptive immunity and strengthens the body’s defence response to viral infections. In an invitro study initiated by Themis, it showed dose-dependent inhibition of viral replication against SARS-CoV-2 (COVID-19).

According to Themis, VIRALEX® will be manufactured at an EU-GMP-certified facility with the highest safety standards and stringent manufacturing protocols in place, and the medication will be available in the form of a 500 mg tablet at a much affordable price.

Speaking at the release, Dr. Sachin Patel, Managing Director & CEO of Themis Medicare Ltd. said, “Our endeavor has always been to develop medicines that benefit patients and make healthcare far, far more effective. Given the current scenario of grave health concerns and economic challenges surrounding COVID-19 in India, this is our effort to contribute to the well being of people of India”.

“Due to the frequently mutating trend of the virus, the uncertainties of the pandemic continue. We hope access to effective treatment such as VIRALEX® will offer a much-needed therapeutic solution, and if initiated early in the disease, it would reduce the load on the healthcare system.”

Commenting on the significance of this development, Dr. Ashok Swain, Head Clinical Development, congratulated the entire Themis Medicare Ltd. team for achieving an important milestone of adding this effective medicine with an established safety profile to address the unmet need in the management of the pandemic.

“VIRALEX® is a new ray of hope in these challenging times,” he said.

Dr Raja Dhar, eminent pulmonologist and Director and Head of Department of Pulmonology, C K Birla Hospitals, said “Inosine Pranobexisa drug which enhances host immunity (immune modulatory effect) and can affect viral RNA and hence inhibits growth of several viruses. Phase 3 Double blind RCTs are rarein COVID 19. I am heartened to hear that Themis Medicare has come up with such a trial, which shows early clinical response and shortened period of recovery when used in mild to moderate COVID19 cases. This drug, if successfully used in clinical practice would considerably reduce the burden on healthcare system.

Dr Dhar is also the current Chair of Training and Education Initiatives, Indian Chest Society, and Director of Research and Training, National Allergy Asthma Bronchitis Institute.

With a strong R&D backup, skilled domestic & export teams, and 4 state-of-the-art manufacturing sites, the endeavour at Themis has always been to support the medical fraternity with solutions for major unmet medical needs like VIRALEX® for COVID-19…and still counting!

About Themis Medicare Ltd

Themis Medicare was incorporated in 1969 as a joint venture partnership at Vapi. Today, it is one of the fastest growing pharma Company specializing in the development of complex molecules. With strong research focus on injectables, complex generic products and drug-delivery systems, the Company has evolved in to being a formidable layer in the complex generics space.

It has a diversified business model with presence across the B2B model and strong presence in domestic B2C market. The Company also has a significant export presence in the RoW geographies. The qualified and experienced Management team is complemented by highly skilled R&D workforce. The Company has three vertically integrated manufacturing facilities, of which two are focused on developing APIs–1 each involved in manufacturing Synthetic API and Fermentation based API, and 1 is involved in manufacturing of Finished Dosage Formulations. Themis offers products in various dosage forms in multiple therapeutics areas with leadership in Pain Management and Critical Care. The Company has a strategy to focus and grow its injectables portfolio and develop its NDDS presence.

For more details, please visit: www.themismedicare.com

Business Tags:Business

Post navigation

Previous Post: India’s F1 hopeful, Jehan Daruvala signs exclusive representation agreement with Meraki Sport & Entertainment Pvt. Ltd
Next Post: IFSCA’s officer becomes the first to acquire a passport displaying the famed address of GIFT city, Gandhinagar

Related Posts

  • Top 4 Luxury Residences to look out for across JVLR-LBS Marg Business
  • Cressanda Solutions Ltd wins prestigious Eastern Railways bid – To advertise Indoor and Exterior of over 500 trains and also provide Concierge Services, Wi-Fi and Content-on-Demand Business
  • NAREDCO Maharashtra Is Set To Host India’s First & Largest Real Estate Property Expo, ‘HOMETHON’ At Jio World Convention Centre In BKC, Mumbai Business
  • Biocon Electric Launches New Range of Switches, Expands Nationwide Business
  • SOLANKI Group Director Mrs. Rekha Solanki Signs MoU Worth 100 Crores with Gujarat Government for Textile Weaving and Polyester Yarn Manufacturing Plant with Advanced Technologies Business
  • Nominations Live for Best Short Film Award | Submit Your Short Film to Win Rs 1,00,000 Cash Prize at Dadasaheb Phalke International Film Festival Business

Recent Posts

  • How Vollsante Is Making Plant-Based Nutrition Mainstream
  • TGPS Infotech: Designing the Digital Framework for a Smarter, Sustainable Future
  • India Prepares to Celebrate Yoga Day at 81 Heritage Sites With Open Access for All
  • BudgetPe’s Digital Magic: Ankit & Rohit Fuel Rs 1,500 Cr Growth in 12 Months
  • “Beyond Compliance”: Vantage & Cyber Skillsphere to Launch New Standards in Cybersecurity Training

Recent Comments

  • Unknown on Participants Reap Rewards in Wellman’s 8-Week Digital Campaign: IPL Tickets, Autographed Virat Kohli Merchandise, and More!
  • Cultural Extravaganza and Monsoon Delights at Saputara Megh Malhar Festival 2024 Lifestyle
  • Five Things to Consider while Investing in Indian Stock Markets in 2023 – Mr. Sidhavelayutham, Founder & CEO, Alice Blue Business
  • Unveiling the Future: Announcing the Prestigious Business Mint Awards for Under 30 and Under 40 Visionary Leaders 2023 Business
  • Revolutionizing Packaging Solutions, Bhavya Plast Unveils Cutting-Edge PET Products Business
  • She Beauty Awards ‘22 presented by Go Stay Digital, celebrated women achievers of Peninsular India Lifestyle
  • IVY Growth associates set to make a mark in the Indian Entrepreneurship Ecosystem in this decade Business
  • A Virus on the Beach: A Captivating Thriller on Goa’s Trafficking Network Business
  • The Role of Homeopathy in Integrated Medicine Business

Copyright © 2025 Daily News India.

Powered by PressBook News WordPress theme